The Feinstein Institute for Medical Research
Manhasset, New York, 11030, United States
Location status: Recruiting
Recruiting
NCT Number: NCT00902447
Human Blood Cell Disorders Tissue Bank
The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.
Recruiting
Interested in participating?
Request InfoKey information
Age range
18 year–100 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent.
- Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care.
- Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care.
Exclusion criteria
- Patients who are known to be anemic, with hemoglobin <8.0g/dl.
- Patients who are known to be infected with HIV.
Treatment and study plan
Primary outcomes
-
Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions.
Time frame: Indefinite
Secondary outcomes
-
Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future.
Time frame: Indefinite
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Northwell Health
Other
Registry information
Important dates
- Study start
- 2009
- Primary completion
- 2030
- Study completion
- 2035
- First posted
- May 15, 2009
- Registry last updated
- Mar 27, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.